RC 3095

Known as: RC-3095 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1991-2017
051019912017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
OBJECTIVE To evaluate the antiinflammatory effects of RC-3095 in 2 experimental models of arthritis, collagen-induced arthritis… (More)
Is this relevant?
2004
2004
Bombesin and its mammalian equivalent, gastrin-releasing peptide (GRP), stimulate cell proliferation and are involved in the… (More)
Is this relevant?
2003
2003
Bombesin (BN)-like peptides regulate cell proliferation and cancer growth as well as neuroendocrine and neural functions. We… (More)
Is this relevant?
1997
1997
Antagonists of bombesin/gastrin-releasing peptide (BN/GRP) have been developed to inhibit the stimulatory effects of BN/GRP on… (More)
Is this relevant?
1994
1994
Nude mice bearing xenografts of the gastrin-responsive human gastric carcinoma MKN45 cell line were treated for 4 to 5 weeks with… (More)
Is this relevant?
1994
1994
In this study, we investigated the effect of bombesin/GRP antagonist RC-3095 on the growth of CFPAC-1 human pancreatic cancer… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
1992
1992
Recently, it was reported that bombesin/gastrin-releasing peptide (GRP) have mitogenic effects on some human breast cancer cell… (More)
  • figure 2
  • table 1
  • figure 1
  • table 2
Is this relevant?
1992
1992
The effects of treatment with a bombesin receptor antagonist [D-Tpi6, Leu13 psi (CH2NH) Leu14]BN(6-14)(RC-3095) and the… (More)
Is this relevant?
1992
1992
BACKGROUND Many breast cancers are estrogen independent, and even in patients who initially respond to estrogen suppression… (More)
Is this relevant?
1991
1991
Nude mice bearing xenografts of HT-29 human colon cancer cell line were treated for 4 weeks with a [D-Trp6] agonist of… (More)
Is this relevant?